Comparison of Ultrasound therapy and Injection Treatment in managing oral submucous fibrosis

A comparative study of efficacy of Therapeutic Ultrasound therapy and Intralesional Injection in patients with oral submucous fibrosis - a clinical trial study - NIL

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/10/096691

Enrollment

Registered

2025-10-31

Start date

Unknown

Completion date

Unknown

Last updated

2026-01-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K135- Oral submucous fibrosis

Interventions

Intervention1: This study is to assess the effects of intralesional injection of dexamethasone, hyaluronidase and adjuvant therapeutic ultrasonography with physical therapy and in the treatment of per

Eligibility

Inclusion criteria

Inclusion criteria: a. All age group patient. b. Clinically diagnosed with OSMF

Exclusion criteria

Exclusion criteria: a. The existence of any additional illnesses, such as tetany or systemic sclerosis b. The history of radiation therapy c. The history of OSMF medicinal or surgical treatment d. The existence of systemic disease

Design outcomes

Primary

Measure	Time frame
The study aims to determine which treatment therapy, along with regular mouth opening exercises and a cessation of the betel quid chewing habit, will proven to be essential for managing OSMF cases in both the early and severe stages of advancement. In individuals with OSMF, the therapeutic ultrasound will show significant impact on all the parameters including cheek flexibility and mouth opening and it will be works well as an adjuvant in conjunction with combination therapy. Timepoint: at baseline 4 weeks and 6 months	—

Measure

Time frame

The study aims to determine which treatment therapy, along with regular mouth opening exercises and a cessation of the betel quid chewing habit, will proven to be essential for managing OSMF cases in both the early and severe stages of advancement. In individuals with OSMF, the therapeutic ultrasound will show significant impact on all the parameters including cheek flexibility and mouth opening and it will be works well as an adjuvant in conjunction with combination therapy. Timepoint: at baseline 4 weeks and 6 months

—

Secondary

Measure	Time frame
NILTimepoint: NIL	—

Countries

India

Contacts

Public ContactDr Nikita Waghmare

SMBT dental college and hospital ghulewadi Sangamner

drshital1987@gmail.com9028813698

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026